{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2009"],"condition":["Second-Line Treatment for Metastatic Colorectal Cancer","Colorectal Cancer (CRC)","Colorectal Neoplasms","Metastatic colorectal cancer"],"disease":["Metastatic Colorectal Cancer","Second-line Treatment For Metastatic Colorectal Cancer","Colorectal Cancer (crc)","Colorectal Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2068498"],"location":["Argentina","United States","Italy","France"],"study_start_month":["10"],"keyword":["Irinotecan","Calcium","Irinotecan Hydrochloride, trihydrate","Levoleucovorin","Leucovorin","Neofolin","5-FU Hexal","Pharmaceutical Solutions","CT-322","Fluorouracil","Bevacizumab"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer","description":"The purpose of this study is to determine the efficacy of CT-322 comparative to bevacizumab, both in combination with irinotecan, 5-FU and leucovorin in the second-line treatment of subject with metastatic colorectal cancer","dates":{"creation":"2009-10-15"},"accession":"2068498","cross_references":{"ClinicalTrials___gov":["NCT00851045"],"EU Clinical Trials Register":["2008-006561-89"]}}